Handelsbanken Fonder AB Invests $4.82 Million in NewAmsterdam Pharma (NASDAQ:NAMS)

Handelsbanken Fonder AB bought a new position in shares of NewAmsterdam Pharma (NASDAQ:NAMS) in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm bought 187,404 shares of the company’s stock, valued at approximately $4,816,000. Handelsbanken Fonder AB owned about 0.20% of NewAmsterdam Pharma as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds also recently modified their holdings of the company. Mirae Asset Global Investments Co. Ltd. acquired a new stake in shares of NewAmsterdam Pharma during the 4th quarter worth about $80,000. Quarry LP lifted its stake in shares of NewAmsterdam Pharma by 2,469.2% during the 3rd quarter. Quarry LP now owns 6,500 shares of the company’s stock worth $108,000 after buying an additional 6,247 shares during the last quarter. Barclays PLC lifted its stake in shares of NewAmsterdam Pharma by 1,813.4% during the 3rd quarter. Barclays PLC now owns 7,596 shares of the company’s stock worth $126,000 after buying an additional 7,199 shares during the last quarter. Bellevue Group AG acquired a new stake in shares of NewAmsterdam Pharma during the 3rd quarter worth about $128,000. Finally, HB Wealth Management LLC acquired a new stake in shares of NewAmsterdam Pharma during the 4th quarter worth about $224,000. Institutional investors and hedge funds own 89.89% of the company’s stock.

NewAmsterdam Pharma Price Performance

NAMS stock opened at $18.57 on Monday. NewAmsterdam Pharma has a 12 month low of $15.19 and a 12 month high of $27.29. The company’s 50-day moving average price is $23.17 and its two-hundred day moving average price is $20.24.

Insider Buying and Selling at NewAmsterdam Pharma

In other NewAmsterdam Pharma news, major shareholder Nap B.V. Forgrowth sold 100,728 shares of the firm’s stock in a transaction dated Wednesday, December 18th. The shares were sold at an average price of $26.10, for a total value of $2,629,000.80. Following the transaction, the insider now directly owns 10,908,502 shares of the company’s stock, valued at $284,711,902.20. This trade represents a 0.91 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders have sold a total of 404,927 shares of company stock valued at $10,390,787 in the last ninety days. 19.50% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

Several brokerages have weighed in on NAMS. Scotiabank lifted their price objective on shares of NewAmsterdam Pharma from $35.00 to $47.00 and gave the stock a “sector outperform” rating in a research note on Wednesday, December 11th. HC Wainwright reiterated a “buy” rating and issued a $48.00 price objective on shares of NewAmsterdam Pharma in a research note on Tuesday, January 14th. Needham & Company LLC reiterated a “buy” rating and issued a $36.00 price objective on shares of NewAmsterdam Pharma in a research note on Thursday, December 5th. Finally, Royal Bank of Canada reiterated an “outperform” rating and issued a $40.00 price objective on shares of NewAmsterdam Pharma in a research note on Friday, January 24th. Six investment analysts have rated the stock with a buy rating, According to MarketBeat, the stock currently has an average rating of “Buy” and a consensus target price of $41.60.

About NewAmsterdam Pharma

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.